Cargando…
Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1
Gastric cancer (GC) is a leading cause of death worldwide and in urgent need of targeted drug development. In the current, we investigated the ability of a repositioned drug verteporfin (VP), originally a treatment for macular degeneration, to inhibit GC cell growth. VP inhibited growth of various G...
Autores principales: | Kang, Myoung-Hee, Jeong, Gi Seok, Smoot, Duane T., Ashktorab, Hassan, Hwang, Chang Mo, Kim, Byung Sik, Kim, Hee Sung, Park, Yun-Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716775/ https://www.ncbi.nlm.nih.gov/pubmed/29228735 http://dx.doi.org/10.18632/oncotarget.21946 |
Ejemplares similares
-
Correction: Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1
por: Kang, Myoung-Hee, et al.
Publicado: (2018) -
Screening and Identification of Peptides Specifically Targeted to Gastric Cancer Cells from a Phage Display Peptide Library
por: Sahin, Deniz, et al.
Publicado: (2018) -
Molecular Signatures of JMJD10/MINA53 in Gastric Cancer
por: Aziz, Nur, et al.
Publicado: (2020) -
NKX6.3 protects against gastric mucosal atrophy by downregulating β-amyloid production
por: Yoon, Jung Hwan, et al.
Publicado: (2019) -
Multiple genetic mutations caused by NKX6.3 depletion contribute to gastric tumorigenesis
por: Yoon, Jung Hwan, et al.
Publicado: (2018)